The invention concerns a pharmaceutical composition for treating a viral infection caused by a member of the Reoviridae family; a method of treatment involving the use of same and use of the anti-viral to treat said viral infection. The agent has use in both humans and animals.

The present invention provides mammalian cell lines that have been genetically engineered causing such cell lines to be resistant to viral entry and/or propagation, and provides methods of using said cell lines to reduce or prevent viral contamination of biologic production systems.

Compositions and methods are provided relating to rotavirus serotypes and antibodies that bind to human rotavirus and modifications thereto which enhance the immunogenicity of the rotavirus protein for vaccine development with respect to the generation of a neutralizing immune response. Further disclosed are methods of using the antibodies for treating a rotavirus-mediated disease in a subject.